How Large Is Research Solutions' (NASDAQ:RSSS) $1 Million Scite Deal?

Sonal Goyal

12 November 2026 12:11 PM AEDT

How Large Is Research Solutions' (NASDAQ:RSSS) $1 Million Scite Deal?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

The enterprise Scite agreement is valued at $1 million.
The counterparty is a Fortune 500 biopharmaceutical company.
The company describes the deal as the largest in its history.
The agreement expands an existing Article Galaxy relationship into a full Scite rollout.

Research Solutions (NASDAQ:RSSS), a provider of SaaS and AI-powered scientific research tools, has signed what it describes as the largest agreement in its history. The contract, valued at $1 million, is with a Fortune 500 biopharmaceutical company and was reported on November 11, 2026. The deal extends a longstanding relationship and points to Demand from pharmaceutical research teams for AI tools grounded in scientific literature. Scientific literature platforms Supply the source material that research teams and AI systems use to answer questions. As pharmaceutical companies test AI tools for drug discovery and regulatory work, the quality and traceability of the sources they draw on have become a central concern.

Scope of the Enterprise Rollout

The agreement expands the customer's existing Article Galaxy relationship into a full enterprise deployment of Scite across all of its research groups. The arrangement gives researchers and internal tools access to Scite's Smart Citations and scientific literature search.

The package also includes full Scite API access, allowing the customer's internal systems to draw on the same literature base.

Enterprise deployments of research software usually involve larger user counts, more integrations and longer contract periods than departmental purchases. The expansion from a single relationship into a company-wide rollout reflects how a customer has moved from testing to broader use.

Why Pharma Teams Need Source-Grounded AI

The company said large Research and Development organizations are building systems for evidence-based literature search, mechanism-of-action research, Patent landscaping and pharmacovigilance. General-purpose AI models, it noted, have limited coverage of scholarly content, can generate citations that do not exist and cannot always separate supported findings from contested ones.

Scite is positioned to address those gaps at the infrastructure level, according to the company.

Citation accuracy is a practical issue for AI systems, since a model that cites non-existent or misattributed sources can mislead users. The company's emphasis on source-grounded answers addresses that issue directly for customers that need evidence trails.

Evaluation Process and Open Points

The agreement followed a months-long enterprise evaluation that included live demonstrations, a technical trial and reviews by procurement, legal, information security, technical architecture and the customer's AI governance function, before executive approval.

The disclosure does not state the contract term, the timing of Revenue recognition or how the agreement compares with the company's total revenue.

Pharmacovigilance monitors the safety of medicines after they reach the market, and mechanism-of-action research examines how a drug works in the body. Both areas depend on large volumes of published research, which is why they are among the uses cited for enterprise literature tools.

Company Scale and Revenue Mix

Research Solutions describes itself as a provider of SaaS and AI-powered research tools. The company calls this agreement the largest in its history, although the update does not state its share of annual revenue.

Multi-year enterprise contracts can provide more predictable revenue than single purchases, but the update does not indicate whether this agreement is recurring or one-time. The contract terms will determine how the value is recognized over time.

Final Word

Research Solutions has signed a $1 million enterprise agreement that deepens a pharmaceutical customer relationship and adds API access to its scientific literature platform. The disclosed figures do not show the contract term, the timing of revenue or the total revenue impact. Future quarterly results will indicate whether the company's pipeline produces more contracts of this size. The deal shows how the company is positioning its platform for organizations that need AI tools tied to published evidence.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.